HAMBURG, Germany--(BUSINESS WIRE)--Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced the achievement of a key pre-clinical milestone in the ongoing alliance with its research partner Padlock Therapeutics, Inc. (“Padlock”). The programme focuses on developing inhibitors of protein-arginine deiminases (“PADs”), first-in-class compounds for autoimmune diseases such as rheumatoid arthritis (RA) and lupus. The milestone triggers a significant milestone payment to Evotec.
